News
07-22-2010, 05:20 AM
Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients.
More... (http://www.news-medical.net/news/20100722/Merrimack-sanofi-aventis-initiate-dosing-in-MM-121-and-exemestane-combination-Phase-2-breast-cancer-study.aspx)
More... (http://www.news-medical.net/news/20100722/Merrimack-sanofi-aventis-initiate-dosing-in-MM-121-and-exemestane-combination-Phase-2-breast-cancer-study.aspx)